Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid Infusion Rituximab in Autoimmune Diseases
NCT02040116Phase 4Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Feb 2013
- Primary completion
- Aug 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in autoimmune disease and multiple sclerosis (MS), sponsored by Wake Forest University Health Sciences. Primary endpoints: Incidence of Infusion Related Reactions With Rapid Infusion at 14 days and Grade of Infusion Related Reactions With Rapid Infusion at 14 days. Started Feb 2013; status: completed.
02
Drugs
rituximab
03
Conditions
autoimmune diseasemultiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02040116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02040116.